Abstract
Durgama Anchalare Malaria Nirakaran (DAMaN) is a multi-component malaria intervention for hard-to-reach villages in Odisha, India. The main component, Malaria Camps (MCs), consists of mass screening, treatment, education, and intensified vector control. We evaluated MC effectiveness using a quasi-experimental cluster-assigned stepped-wedge study with a pretest-posttest control group in 15 villages: six immediate (Arm A), six delayed (Arm B), and three previous interventions (Arm C). The primary outcome was PCR+ Plasmodium infection prevalence. Across all arms, the odds of PCR+ malaria were 54% lower at the third follow-up compared to baseline. A time (i.e., visit) x study arm interaction revealed significantly lower odds of PCR+ malaria in Arm A versus B at the third follow-up. The cost per person ranged between US$3-8, the cost per tested US$4-7, and the cost per treated US$82-1,614, per camp round. These results suggest that the DAMaN intervention is a promising, financially feasible approach for malaria control.
Competing Interest Statement
Dr. Madan M. Pradhan is employed by the Odisha State Vector Borne Disease Control Programme, which is the organization that is implementing the intervention. He has a potentially self-serving stake in the research results via potential promotion or career advancement based on outcomes. The other authors have no competing interests to declare.
Clinical Trial
NCT03963869
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/33866961/
Funding Statement
This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number U19AI089676 as part of the International Centers of Excellence for Malaria Research. The content does not necessarily represent the official views of the US NIH or NIAID.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the trial was obtained from the Odisha State Research and Ethics Committee (Odisha, India), institutional ethics committee at Community Welfare Society Hospital (Rourkela, Odisha, India) and the institutional review board at New York University (New York, NY, USA). All research was performed in accordance with relevant guidelines/regulations and the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Epidemiology study data are available in the Clinical Epidemiology Database (https://clinepidb.org) under the India ICEMR DAMaN Quasi-experimental Stepped-wedge study title.
